2 completed, 1 active not recruiting, 1 unknown. 4 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 2, Active not recruiting 1, Unknown 1 |
| Phase 1 | 2 | Completed 1, Unknown 1 |
Follow Inhibition, Psychological: new trials by email Literature Review of Inhibition, Psychological trials Research Report on Inhibition, Psychological
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Janus Kinase Inhibition in Granuloma Annulare Abrocitinib 200 mg - Granuloma Annulare | Phase 2 | Completed | William Damsky | 10 | 2023-10-27 | 2026-10-07 |
| Tazemetostat in Malignant Peripheral Nerve Sheath Tumors Tazemetostat - Peripheral Nerve Sheath Tumor | Phase 2 | Active not recruiting | University of Florida | 10 | 2021-08-25 | 2026-06-04 |
| An Open-Label Phase 1/2 Study of Itacitinib in Combination With Osimertinib in Subjects With Non-Small Cell Lung Cancer Itacitinib, Osimertinib - Lung Cancer | Phase 1 / Phase 2 | Completed | Incyte Corporation | 59 | 2016-12-20 | 2026-02-09 |
| Low-dose vs. Normal-dose Psychostimulants on Executive Functions in Individuals With ADHD Psychostimulants - Attention Deficit Hyperactivity Disorders | Phase 1 / Phase 2 | Unknown | University of British Columbia | 52 | 2014-06-01 | 2024-05-08 |
Attention Deficit Disorder with Hyperactivity (1) · Carcinoma, Non-Small-Cell Lung (1) · Granuloma Annulare (1) · Lung Neoplasms (1) · Neoplasm Metastasis (1) · Nerve Sheath Neoplasms (1) · Neurofibrosarcoma (1) · Sarcoma (1)
Behavior (4) · Neoplasms (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Attention Deficit and Disruptive Behavior Disorders (1) · Bronchial Neoplasms (1) · Carcinoma, Bronchogenic (1) · Collagen Diseases (1) · Connective Tissue Diseases (1) · Fibrosarcoma (1) · Granuloma (1) · Lung Diseases (1) · Mental Disorders (1) · Necrobiotic Disorders (1) · Neoplasms by Histologic Type (1)
INCB039110 (1) · abrocitinib (1) · itacitinib (1) · osimertinib (1) · tazemetostat (1)
Incyte Corporation (1) · University of British Columbia (1) · University of Florida (1) · William Damsky (1)
United States (3) · Canada (1) · South Korea (1) · Spain (1) · Taiwan (1)
Adele Diamond, Ph.D. (1) · Joanne Lagmay, MD (1) · Peter Langmuir (1) · William Damsky, M.D. (1)
2017 (1)